Toward hypotheses for a biochemical component in the vulnerability to schizophrenia.
D000661:Amphetamine / Q000494:pharmacology; D014150:Antipsychotic Agents / Q000494:pharmacology; D001921:Brain / Q000378:metabolism; D002090:Butyrophenones / Q000494:pharmacology; D004198:Disease Susceptibility; D004298:Dopamine / Q000378:metabolism / Q000502:physiology; D004299:Dopamine beta-Hydroxylase / Q000378:metabolism; D006212:Hallucinations / Q000209:etiology; D006213:Hallucinogens / Q000378:metabolism; D006801:Humans; D008715:Methionine / Q000378:metabolism; D008745:Methylation; D009638:Norepinephrine / Q000378:metabolism; D010640:Phenothiazines; D011605:Psychoses, Substance-Induced / Q000209:etiology; D011955:Receptors, Drug; D012559:Schizophrenia / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism*; D013329:Structure-Activity Relationship
D014150:Antipsychotic Agents; D002090:Butyrophenones; D006213:Hallucinogens; D010640:Phenothiazines; D011955:Receptors, Drug; D008715:Methionine; D000661:Amphetamine; D004299:Dopamine beta-Hydroxylase; D004298:Dopamine; D009638:Norepinephrine